11.30.22
Frontage Holdings Corp., a contract research organization (CRO) providing science-driven research, analytical, and development services, announced today that Frontage Central Labs has been awarded accreditation from the College of American Pathologists (CAP) after a recent on-site inspection by CAP's Accreditation Programs.
CAP is a leading organization of board-certified pathologists, and its Laboratory Accreditation Program is recognized as the global leader in improving the quality of services using established performance standards. CAP Laboratory Accreditation allows the company to maintain the accuracy of test results, meet, and exceed CLIA, FDA and OSHA standards, and manage evolving changes in lab medicine and technology.
"Frontage Central Labs is committed to the highest standard of quality, and we are proud to have received this accreditation," said Dr. Nan Zhang, the CLIA Laboratory director and VP of Global Central Lab Services. "This is a truly great achievement by the Frontage Central Labs team, which we have received in recognition of the high quality of our services and scientific expertise. As always, we remain dedicated to ensuring the highest standard of patient care and safety possible," said Dr. John Lin, EVP and Global Head, Bioanalytical and Biologics Services.
CAP is a leading organization of board-certified pathologists, and its Laboratory Accreditation Program is recognized as the global leader in improving the quality of services using established performance standards. CAP Laboratory Accreditation allows the company to maintain the accuracy of test results, meet, and exceed CLIA, FDA and OSHA standards, and manage evolving changes in lab medicine and technology.
"Frontage Central Labs is committed to the highest standard of quality, and we are proud to have received this accreditation," said Dr. Nan Zhang, the CLIA Laboratory director and VP of Global Central Lab Services. "This is a truly great achievement by the Frontage Central Labs team, which we have received in recognition of the high quality of our services and scientific expertise. As always, we remain dedicated to ensuring the highest standard of patient care and safety possible," said Dr. John Lin, EVP and Global Head, Bioanalytical and Biologics Services.